Earnings miss and weak revenue — Sanofi shows bearish price forecast

Traders Union
All News
Financial News
Sanofi rises 0.27% to $86.52 today

Highlights

Sanofi (SAN) trades at $86.52, above its MA-20 and MA-50 but below the MA-200 at $91.09, indicating ongoing long-term bearish pressure despite short-term bullish momentum.
Q2 earnings missed estimates with EPS at $0.90 versus $0.96 expected and revenue down 7% year-over-year to $11.34 billion, reflecting cautious investor sentiment.
Forecasts project Sanofi stock to range between $84.85 and $85.19 over five days, with a less than 20% chance of further price increases and a bearish bias prevailing.

Mixed sentiment persists as earnings miss tempers drug milestone gains

Recent Sanofi earnings missed consensus with an EPS of $0.90 against estimates of $0.96, and revenue fell 7% year-over-year to $11.34 billion, signaling cautious investor sentiment. The company’s rare disease drug candidate, efdoralprin alfa, achieved key study endpoints, with FDA fast track and orphan drug designations supporting Sanofi’s longer-term outlook. Atria Wealth Solutions Inc. also recently sold shares, while the upcoming third quarter earnings presentation scheduled for October 24, 2025, is anticipated to provide additional guidance.

Momentum steadies as support holds and indicators favor mild gains

The nearest dynamic support is the Ichimoku Kijun at $81.60. With the price already above the Kijun and the MA-50 not crossed with the MA-200, no cross signals are present. Momentum indicators show steady bullish undertones: the D1 MACD gives a buy signal, while ADX is neutral, indicating the trend’s strength is limited. Neither major overbought nor oversold conditions appear on daily RSI or Stoch RSI, but some caution is warranted as the CCI points to a positive bias. BBP remains neutral, indicating no dominant side in intraday moves. The Awesome Oscillator supports the bullish picture. Today, the price has risen by $0.23 (up 0.27%) without a significant opening gap, and is currently trading at the very top of today’s range ($85.35 — $86.52), reflecting strength toward highs on low to moderate volatility. Momentum and intraday price action are generally aligned, pointing to mild upward persistence.

Bearish bias forecast as limited upside meets stronger downside risk

Over the next five trading days, the forecasted price range is $84.85 to $85.19 with an average of $85.02. The probability of further price increases is very low (less than 20%). A decline is more likely. The baseline scenario calls for prices to drift sideways around the $85 mark. In the bullish case, a sustained move above $86.50 — $87 could retest higher resistance areas, but this is less probable. The bearish scenario remains dominant, where a fall below the $84.85 support level could trigger further selling toward the lower $84 range.

Viktoras Karapetjanc, expert at Traders Union, notes that Sanofi’s robust short- and medium-term price action is tempered by longer-term resistance and cautious investor sentiment following an earnings miss. He views the company’s progress in rare disease research and supportive regulatory signals as constructive for the fundamental outlook, while recognizing near-term sideways to mild downside risk given recent selling and limited momentum strength. Karapetjanc sees the $84.85 support as the critical threshold, with a modest chance for a breakout above $86.50 if sentiment improves. "Momentum and fundamentals are setting a positive backdrop, but until we see a sustained push above $86.50, consolidative price action around $85 remains my base case."

Last time we reported that the FDA had accepted Sanofi's supplemental biologics license application for Tzield for expedited review. Previously it was noted that technical analysis signaled mixed technical signals as buyers lead despite weak trend strength.

Source of Data: SAN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.